// App-Quantinova.ai

4514 : Avelumab (MSB0010718C; anti-PD-L1) in patients with metastatic urothelial carcinoma from the JAVELIN solid tumor phase 1b trial: Analysis of safety, clinical activity, and PD-L1 expression.

Researchers

Presenter

  • Andrea B. Apolo

Principal Investigators

  • Jeffrey R. Infante

  • Omid Hamid

  • Manish R. Patel

  • Ding Wang

  • Karen Kelly

  • Anthony E. Mega

  • Carolyn D. Britten

  • Alain Ravaud

  • Alain C. Mita

  • Howard Safran

  • Tom Stinchcombe

  • Hans Juergen Grote

  • Anja von Heydebreck

  • Jean-Marie Cuillerot

  • James L. Gulley

Medical Centers

  • Gastrointestinal Malignancies Section, Center for Cancer Research, National Cancer Institute at the National Institutes of Health, Bethesda, MD

  • Sarah Cannon Research Institute, Nashville, TN

  • The Angeles Clinic and Research Institute, Los Angeles, CA

  • Sarah Cannon Research Institute/Florida Cancer Specialists, Sarasota, FL

  • Henry Ford Health System, Detroit, MI

  • UC Davis Comprehensive Cancer Center, Sacramento, CA

  • Alpert Medical School of Brown University, Providence, RI

  • Department of Medicine, Hollings Cancer Center, Medical University of South Carolina, Charleston, SC

  • Hopital Saint-Andre, CHU de Bordeaux, Bordeaux, France

  • Samuel Oschin Comprehensive Cancer Institute at Cedars-Sinai, Los Angeles, CA

  • Miriam Hospital, Providence, RI

  • UNC Chapel Hill, Chapel Hill, NC

  • Merck KGaA, Darmstadt, Germany

  • EMD Serono, Inc, Billerica, MA

  • Genitourinary Malignancies Branch, National Cancer Institute at the National Institutes of Health, Laboratory of Tumor Immunology and Biology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD

Locations

  • United States

  • Germany

  • France

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Advanced Urothelial Carcinoma

  • Solid malignancies

Biomarkers

  • N/A

Drug/Treatment

  • Avelumab

Outcome

  • N/A

Study Design

  • N/A

Phase

  • I

Study Id's

  • NCT01772004

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved